newsfilter
← Latest News
GlobeNewswire·

BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

  • BBO-8520 combined with pembrolizumab achieved a 75% objective response rate (ORR) at the 500 mg QD dose & 53% ORR across all dose levels in 2L+ KRAS G12C inhibitor-experienced NSCLC patients.
  • BBO-8520 monotherapy in 2L+ KRAS G12C inhibitor-naïve NSCLC patients demonstrated a 63% ORR & 100% disease control rate, with 75% of patients on treatment beyond six months.
  • BBO-11818 & BBO-10203 combination cohorts are enrolling in KRAS-mutant colorectal cancer & pancreatic ductal adenocarcinoma.
  • Monotherapy data updates for BBO-11818 & BBO-10203 are expected in the fourth quarter of 2026.
  • Cash, cash equivalents, & marketable securities totaled $315.3 million as of September 30, 2026, providing a cash runway into 2029.
  • Research & development expenses were $29.6 million in Q3 2026, down from $35.1 million in the same period of 2025.
  • General & administrative expenses were $7.9 million in Q3 2026, down from $14.1 million in Q3 2025, driven by reduced payroll & a prior year stock issuance charge.
  • Net loss for Q3 2026 was $34.2 million, compared to $44.8 million in Q3 2025.
Company
TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics)
Keywords
Nasdaq:BBOT, TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics)